FDA Orange Book · active-ingredient family
Granisetron
Granisetron is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:SUSTOL · NDA 022445
2
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · film, extended release, injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| SUSTOLRLD | HERON THERAPS INC | NDA 022445 | — | Aug 09, 2016 | |
| SANCUSORLD | CUMBERLAND | NDA 022198 | — | Sep 12, 2008 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Granisetron — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

